|
Variables
|
No. of studies
|
Test of association
|
Test of heterogeneity
|
|---|
|
HR
|
95% CI
|
P value
|
I2 (%)
|
P value
|
|---|
|
Total
|
9
|
0.598
|
0.465–0.768
|
< 0.001
|
89.00
|
< 0.001
|
|
Publication year
|
|
≤ 2016
|
4
|
0.526
|
0.355–0.777
|
0.001
|
83.10
|
< 0.001
|
|
> 2016
|
5
|
0.66
|
0.470–0.881
|
0.006
|
89.60
|
< 0.001
|
|
Initial inclusion period
|
|
≤ 2006
|
3
|
0.502
|
0.299–0.843
|
0.009
|
88.70
|
< 0.001
|
|
> 2006
|
6
|
0.648
|
0.47–0.882
|
0.006
|
89.60
|
< 0.001
|
|
Nationality
| | | | | | |
|
China
|
8
|
0.561
|
0.466–0.675
|
< 0.001
|
64.40
|
0.006
|
|
Japan
|
1
|
1
|
0.896–1.116
|
1
|
–
|
–
|
|
Number of cases
|
|
< 200
|
4
|
0.684
|
0.450–1.040
|
0.075
|
83.10
|
< 0.001
|
|
> 200
|
5
|
0.551
|
0.429–0.707
|
< 0.001
|
77.60
|
0.001
|
|
Median age (years)
|
|
≤ 60
|
5
|
0.546
|
0.408–0.729
|
< 0.001
|
77.00
|
0.002
|
|
> 60
|
4
|
0.67
|
0.462–0.971
|
0.035
|
87.70
|
< 0.001
|
|
Tumor types
|
|
Cervical carcinoma
|
1
|
0.239
|
0.151–0.379
|
< 0.001
|
–
|
–
|
|
Colon cancer and rectal cancer
|
2
|
0.695
|
0.562–0.861
|
0.001
|
0.00
|
0.713
|
|
Ovarian cancer
|
1
|
0.581
|
0.508–0.664
|
< 0.001
|
–
|
–
|
|
Esophageal cancer
|
1
|
0.461
|
0.31–0.685
|
< 0.001
|
–
|
–
|
|
Lung cancer
|
4
|
0.738
|
0.54–1.007
|
0.056
|
80.00
|
0.002
|
|
LMR cutoff
|
|
≤ 4.0
|
4
|
0.609
|
0.546–0.680
|
< 0.001
|
0.00
|
0.546
|
|
> 4.0
|
5
|
0.56
|
0.351–0.892
|
0.015
|
92.20
|
< 0.001
|
|
Therapeutic strategies
|
|
Chemotherapy
|
4
|
0.62
|
0.558–0.688
|
< 0.001
|
0.00
|
0.489
|
|
Molecular targeted
|
2
|
0.793
|
0.472–1.335
|
0.384
|
84.10
|
0.012
|
|
Combined therapy
|
3
|
0.415
|
0.241–0.716
|
0.002
|
78.40
|
0.01
|
|
Follow-up period (month)
| | | | | | |
|
≤ 33
|
4
|
0.619
|
0.510–0.751
|
< 0.001
|
14.20
|
0.321
|
|
> 33
|
3
|
0.457
|
0.270–0.774
|
0.004
|
85.40
|
0.001
|
|
NR
|
2
|
0.826
|
0.55–1.239
|
0.356
|
88.50
|
0.003
|
|
Quality score
|
|
< 7
|
2
|
0.826
|
0.550–1.239
|
0.356
|
88.50
|
0.003
|
|
≥ 7
|
7
|
0.542
|
0.435–0.674
|
< 0.001
|
67.80
|
0.005
|
|
Analysis of hazard ratio
|
|
Multivariate
|
8
|
0.592
|
0.452–0.776
|
< 0.001
|
90.40
|
< 0.001
|
|
Univariate
|
1
|
0.644
|
0.406–1.021
|
0.061
|
–
|
–
|
- CI confidence interval, HR hazard ratio, No. number; LMR lymphocyte-to-monocyte ratio
